Navigation Links
Tyco Declares Regular Quarterly Dividend
Date:12/4/2008

PEMBROKE, Bermuda, Dec. 4 /PRNewswire-FirstCall/ -- The Board of Directors of Tyco International Ltd. (NYSE: TYC; BSX: TYC) has declared a regular quarterly cash dividend of $0.20 per common share. The dividend is payable on February 2, 2009, to shareholders of record as of January 5, 2009.

ABOUT TYCO INTERNATIONAL

Tyco International (NYSE: TYC) is a diversified, global company that provides vital products and services to customers in more than 60 countries. Tyco is a leading provider of security products and services, fire protection and detection products and services, valves and controls, and other industrial products. Tyco had 2008 revenue of more than $20 billion and has more than 110,000 employees worldwide. More information on Tyco can be found at www.tyco.com.


'/>"/>
SOURCE Tyco International Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
2. BD Board Declares Dividend Increase and Authorizes Additional Share Repurchases
3. Service Corporation International Increases Share Repurchase Authorization to $150 Million and Declares Quarterly Cash Dividend
4. Mesa Labs Declares Quarterly Dividend
5. Schiff(R) Nutrition International Declares November Give Thanks for Grandparents Month
6. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares
7. MSA Declares Fourth Quarter Dividend
8. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
9. Torchmark Corporation Declares Dividend
10. Mylan Declares Quarterly Preferred Stock Dividend
11. NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 2Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 3Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 4Health News:Feeding America and Abbott Partner For Hurricane Relief 2Health News:Feeding America and Abbott Partner For Hurricane Relief 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 2Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 4Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 5Health News:Pain Medicine Experts Recommend Monitoring, Education for All Opioid Medicines 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 3Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 2Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 3
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 1Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 2Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 3Insect resistance to Bt crops can be predicted monitored and managed 61927 1Insect resistance to Bt crops can be predicted monitored and managed 61927 2Research and legislation should go hand in hand as much as possible 10861 1Research and legislation should go hand in hand as much as possible 10861 2